Nara H, Mimori A
Department of Medicine, Jichi Medical School.
Nihon Rinsho. 1999 Feb;57(2):384-7.
Adult onset Still's disease was first reported by Bywaters in 1971. It is a systemic inflammatory disorder of unknown etiology, characterized by spiking fever, macular rash and polyarthritis. Although the prognosis is generally good, severe cases have been published. They include those with disseminated intravascular coagulation (DIC), hemophagocytosis, amyloidosis and respiratory failure. Among them, DIC is not uncommon. Prednisolone in a dose of 20-60 mg/day is required when patients fail to respond to nonsteroidal anti-inflammatory drugs (NSAIDs) or when they are accompanied by complications including pleuritis, pericarditis, liver dysfunction, severe arthritis and DIC. Recently, disease-modifying antirheumatic drugs (DMARDs) and immunosuppressive agents including cyclophosphamide and methotrexate have been shown to be effective for alleviating refractory cases and chronic arthritis.
成人斯蒂尔病于1971年由拜沃特斯首次报道。它是一种病因不明的全身性炎症性疾病,其特征为高热、斑疹和多关节炎。尽管总体预后良好,但也有严重病例的报道。这些病例包括伴有弥散性血管内凝血(DIC)、噬血细胞增多症、淀粉样变性和呼吸衰竭的患者。其中,DIC并不少见。当患者对非甾体抗炎药(NSAIDs)无反应或伴有胸膜炎、心包炎、肝功能不全、严重关节炎和DIC等并发症时,需要使用剂量为20 - 60毫克/天的泼尼松龙。最近,改善病情抗风湿药(DMARDs)以及包括环磷酰胺和甲氨蝶呤在内的免疫抑制剂已被证明对缓解难治性病例和慢性关节炎有效。